Model-based treatment optimization of a novel VEGFR inhibitor
Author:
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2125.2012.04197.x/fullpdf
Reference43 articles.
1. Tumor angiogenesis: therapeutic implications;Folkman;N Engl J Med,1971
2. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer;Yang;N Engl J Med,2003
3. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease;Fiedler;Blood,2005
4. Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584;Thomas;Semin Oncol,2003
5. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis;Zhu;Am J Kidney Dis,2007
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Population Pharmacokinetic Modeling of Lucitanib in Patients with Advanced Cancer;European Journal of Drug Metabolism and Pharmacokinetics;2022-07-18
2. Pharmacodynamic analysis of hypertension caused by lenvatinib using real‐world postmarketing surveillance data;CPT: Pharmacometrics & Systems Pharmacology;2021-02-14
3. Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan;Advances in Therapy;2020-07-16
4. Drug-Related Hypertension Associated with the Efficacy of Apatinib on Hepatocellular Carcinoma;Cancer Management and Research;2020-05
Drug-Related Hypertension Associated with the Efficacy of Apatinib on Hepatocellular Carcinoma
5. Dosage Optimization of Nemolizumab Using Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling and Simulation;The Journal of Clinical Pharmacology;2017-07-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3